Bioxytran (BIXT) EBIT Growth (5y) (2015 - 2026)
Bioxytran (BIXT) EBIT Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.79 Bn | 131.94 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.74 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.48 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 59.32 Bn | 54.18 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.81 Bn | 28.50 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.56 Bn | 26.40 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.74% |
| Dec 31, 2025 | 4.79% |
| Sep 30, 2025 | -34.08% |
| Jun 30, 2025 | -14.90% |
| Mar 31, 2025 | -14.13% |
| Dec 31, 2024 | 0.46% |
| Sep 30, 2024 | 16.45% |
| Jun 30, 2024 | -41.74% |
| Mar 31, 2024 | -43.15% |
| Dec 31, 2023 | -43.30% |
| Sep 30, 2023 | -83.38% |
| Jun 30, 2023 | -421.20% |
| Mar 31, 2023 | -307.22% |
| Dec 31, 2022 | -66.16% |
| Sep 30, 2022 | -22.49% |
| Jun 30, 2022 | -15.76% |
| Mar 31, 2022 | -67.23% |
| Dec 31, 2021 | -54.56% |
| Sep 30, 2021 | -20.88% |
| Jun 30, 2021 | -48.70% |